BMY catalyst calendar

BRISTOL MYERS SQUIBB CO

Upcoming catalysts
16
Cash runway
Cash generating
Cash & investments
$8722M
Phase 3 programs
26

BRISTOL MYERS SQUIBB CO is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus on October 19, 2026. There are 16 upcoming events on record.

BRISTOL MYERS SQUIBB CO generates cash from operations, so a burn-based runway figure does not apply.

Across 279 concluded trials, 87% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 19, 2026 A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus Trial Milestone Phase 3
October 29, 2026 est. Next quarterly earnings (projected) Earnings —
November 1, 2026 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Trial Milestone Phase 3
December 17, 2026 A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants Trial Milestone Phase 1
March 11, 2027 A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer Trial Milestone Phase 3
March 29, 2027 A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses Trial Milestone Phase 1
June 1, 2027 Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants Trial Milestone Phase 1
August 1, 2028 A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma Trial Milestone Phase 1
October 13, 2028 A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies Trial Milestone Phase 1/Phase 2
November 24, 2028 A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) Trial Milestone Phase 3
December 14, 2028 A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors Trial Milestone Phase 1
December 29, 2028 A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9) Trial Milestone Phase 2
January 26, 2029 Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy Trial Milestone Phase 2/Phase 3
June 22, 2029 A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) Trial Milestone Phase 3
August 6, 2029 A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder Trial Milestone Phase 3
October 18, 2030 A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) Trial Milestone Phase 1

Track BMY alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open BMY in the tracker

Recent history

DateEventTypePhase
October 12, 2026 A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma Trial Milestone Phase 1/Phase 2
September 28, 2026 A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) Trial Milestone Phase 3
August 28, 2026 Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Trial Milestone Phase 1
July 30, 2026 Quarterly results filed (8-K) Earnings —
July 16, 2026 A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy Trial Milestone Phase 4
July 9, 2026 A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Trial Milestone Phase 3
April 30, 2026 Quarterly results filed (8-K) Earnings —
February 5, 2026 Quarterly results filed (8-K) Earnings —
January 12, 2026 8-K filed: Reg FD disclosure Filing —
November 18, 2025 8-K filed: Other event Filing —
November 10, 2025 8-K filed: Other event Filing —
November 3, 2025 8-K filed: Other event Filing —
October 30, 2025 Quarterly results filed (8-K) Earnings —
September 11, 2025 A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants Trial Milestone Phase 1
August 1, 2025 A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia. Trial Milestone Phase 2
July 31, 2025 Quarterly results filed (8-K) Earnings —
July 25, 2025 8-K filed: Leadership change Corporate —
July 22, 2025 Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders Trial Milestone Phase 1
April 24, 2025 Quarterly results filed (8-K) Earnings —
April 20, 2025 A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies Trial Milestone Phase 1
February 19, 2025 Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants Trial Milestone Phase 1
December 16, 2024 A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma Trial Milestone Phase 3
October 25, 2024 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Trial Milestone Phase 3
October 16, 2024 A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants Trial Milestone Phase 1
September 13, 2024 A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy Trial Milestone Phase 2/Phase 3
August 28, 2024 A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) Trial Milestone Phase 3
August 23, 2024 A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting Trial Milestone Phase 4
August 22, 2024 A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors Trial Milestone Phase 1/Phase 2
August 19, 2024 A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy Trial Milestone Phase 2
July 30, 2024 A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.